Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis.

Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S, Zamboni G, Valentini R, Tató L

The Journal of pediatrics1 Sept 1996Cited by 52 (Europe PMC)

PMID8804334DOI10.1016/s0022-3476(96)70077-xPepBankPUB-08804334

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with type I osteogenesis imperfecta, growth velocity after hGH exceeded the untreated group's velocity (p < 0.05).
In plain wordsIn children with type I osteogenesis imperfecta, hGH increased growth velocity compared with the untreated group.
Peptide
HGH (somatotropin)
Outcome
IncreaseLinear growth velocity versus untreated group
Study
n = 14
Comparator
Untreated group
Outcome group
Linear growth · Musculoskeletal
Studied dose
0.2 mg/kg per week (0.6 IU/kg per week), in six injections · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
After 12 months, linear growth velocity in treated patients increased significantly in comparison with the pretreatment period (from 3.57 +/- 0.55 to 6.04 +/- 0.69 cm/yr; p < 0.05) and with the untreated group (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Fourteen patients (6 boys; ages 4.8 to 10.8 years) were studied.
Summary · context
The patients were divided into two groups comparable in sex, age, height, and clinical severity of OI; seven patients (three boys) were treated for 12 months with hGH at a dosage of 0.2 mg/kg per week (0.6 IU/kg per week), in six injections subcutaneously, and seven were followed as control subjects.
Report a problemFND-0880433402
02HumanNon-randomized trialEfficacy outcome
In children with type I osteogenesis imperfecta, hGH increased growth velocity from 3.57 +/- 0.55 to 6.04 +/- 0.69 cm/yr (p < 0.05).
In plain wordsIn children with type I osteogenesis imperfecta, growth velocity increased during hGH treatment compared with pretreatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseLinear growth velocity versus pretreatment
Study
n = 7
Comparator
Pretreatment
Outcome group
Linear growth · Musculoskeletal
Studied dose
0.2 mg/kg per week (0.6 IU/kg per week), in six injections · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Growth velocity
3.57 cm/yr
pretreatment
Growth velocity
6.04 cm/yr
after 12 months
Source sentences
Summary
After 12 months, linear growth velocity in treated patients increased significantly in comparison with the pretreatment period (from 3.57 +/- 0.55 to 6.04 +/- 0.69 cm/yr; p < 0.05) and with the untreated group (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Fourteen patients (6 boys; ages 4.8 to 10.8 years) were studied.
Summary · context
The patients were divided into two groups comparable in sex, age, height, and clinical severity of OI; seven patients (three boys) were treated for 12 months with hGH at a dosage of 0.2 mg/kg per week (0.6 IU/kg per week), in six injections subcutaneously, and seven were followed as control subjects.
Report a problemFND-0880433401
03HumanNon-randomized trialEfficacy outcome
In children with type I osteogenesis imperfecta receiving hGH, bone age did not advance faster than chronologic age.
In plain wordsIn children with type I osteogenesis imperfecta receiving hGH, bone age did not advance faster than chronologic age.
Peptide
HGH (somatotropin)
Outcome
No significant changeBone age advancement
Study
n = 7
Comparator
Chronologic age
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.2 mg/kg per week (0.6 IU/kg per week), in six injections · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Bone age did not advance faster than chronologic age.
2 context sentences(design, population, supporting numbers)
Summary · context
Fourteen patients (6 boys; ages 4.8 to 10.8 years) were studied.
Summary · context
The patients were divided into two groups comparable in sex, age, height, and clinical severity of OI; seven patients (three boys) were treated for 12 months with hGH at a dosage of 0.2 mg/kg per week (0.6 IU/kg per week), in six injections subcutaneously, and seven were followed as control subjects.
Report a problemFND-0880433403
04HumanNon-randomized trialSafety outcome
In children with type I osteogenesis imperfecta, no hGH-treated patient had a fracture during therapy.
In plain wordsIn children with type I osteogenesis imperfecta, no patient had a fracture during hGH treatment.
Peptide
HGH (somatotropin)
Outcome
Not applicableFractures during treatment
Study
n = 7
Outcome group
Adverse events · Musculoskeletal
Studied dose
0.2 mg/kg per week (0.6 IU/kg per week), in six injections · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
The fracture index per year was low before treatment, and during therapy no patient had any fractures.
2 context sentences(design, population, supporting numbers)
Summary · context
Fourteen patients (6 boys; ages 4.8 to 10.8 years) were studied.
Summary · context
The patients were divided into two groups comparable in sex, age, height, and clinical severity of OI; seven patients (three boys) were treated for 12 months with hGH at a dosage of 0.2 mg/kg per week (0.6 IU/kg per week), in six injections subcutaneously, and seven were followed as control subjects.
Report a problemFND-0880433404
05HumanNon-randomized trialEfficacy outcome
In children with type I osteogenesis imperfecta, osteocalcin increased after hGH to 3.3 +/- 1.0 versus 2.1 +/- 0.9 nmol/L (p < 0.05).
In plain wordsIn children with type I osteogenesis imperfecta, serum osteocalcin increased after hGH compared with pretreatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum osteocalcin
Study
n = 7
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.2 mg/kg per week (0.6 IU/kg per week), in six injections · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Osteocalcin
3.3 nmol/L
after 12 months
Osteocalcin
2.1 nmol/L
pretreatment
Source sentences
Summary
Serum osteocalcin levels were statistically lower than in control subjects before treatment and increased significantly after 12 months (3.3 +/- 1.0 vs 2.1 +/- 0.9 nmol/L; p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Fourteen patients (6 boys; ages 4.8 to 10.8 years) were studied.
Summary · context
The patients were divided into two groups comparable in sex, age, height, and clinical severity of OI; seven patients (three boys) were treated for 12 months with hGH at a dosage of 0.2 mg/kg per week (0.6 IU/kg per week), in six injections subcutaneously, and seven were followed as control subjects.
Report a problemFND-0880433405
06HumanNon-randomized trialEfficacy outcome
In children with type I osteogenesis imperfecta, serum type I procollagen carboxyterminal propeptide rose nonsignificantly during and after hGH.
In plain wordsIn children with type I osteogenesis imperfecta, serum type I procollagen carboxyterminal propeptide did not change significantly during or after hGH.
Peptide
HGH (somatotropin)
Outcome
No significant changeSerum type I procollagen carboxyterminal propeptide
Study
n = 7
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.2 mg/kg per week (0.6 IU/kg per week), in six injections · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Serum levels of carboxyterminal propeptide of type I procollagen were significantly lower than normal values before treatment (164.6 +/- 46.7 vs 310.3 +/- 97.6 ng/ml; p < 0.05) and rose, but not significantly, during and after treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Fourteen patients (6 boys; ages 4.8 to 10.8 years) were studied.
Summary · context
The patients were divided into two groups comparable in sex, age, height, and clinical severity of OI; seven patients (three boys) were treated for 12 months with hGH at a dosage of 0.2 mg/kg per week (0.6 IU/kg per week), in six injections subcutaneously, and seven were followed as control subjects.
Report a problemFND-0880433406
07HumanNon-randomized trialEfficacy outcome
In children with type I osteogenesis imperfecta, lumbar anteroposterior bone density increased by 2.6 +/- 2.5% after hGH (p < 0.05).
In plain wordsIn children with type I osteogenesis imperfecta, lumbar anteroposterior bone density increased after hGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseLumbar anteroposterior bone density
Study
n = 7
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.2 mg/kg per week (0.6 IU/kg per week), in six injections · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Anteroposterior bone density increase
2.6%
after hGH
Source sentences
Summary
After hGH treatment, bone density increased significantly in the lumbar spine, in anteroposterior and lateral scans (+2.6 +/- 2.5% and +9.8% +/- 14.0%, respectively; p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Fourteen patients (6 boys; ages 4.8 to 10.8 years) were studied.
Summary · context
The patients were divided into two groups comparable in sex, age, height, and clinical severity of OI; seven patients (three boys) were treated for 12 months with hGH at a dosage of 0.2 mg/kg per week (0.6 IU/kg per week), in six injections subcutaneously, and seven were followed as control subjects.
Report a problemFND-0880433407
08HumanNon-randomized trialEfficacy outcome
In children with type I osteogenesis imperfecta, lumbar lateral bone density increased by 9.8% +/- 14.0% after hGH (p < 0.05).
In plain wordsIn children with type I osteogenesis imperfecta, lumbar lateral bone density increased after hGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseLumbar lateral bone density
Study
n = 7
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.2 mg/kg per week (0.6 IU/kg per week), in six injections · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Lateral bone density increase
9.8%
after hGH
Source sentences
Summary
After hGH treatment, bone density increased significantly in the lumbar spine, in anteroposterior and lateral scans (+2.6 +/- 2.5% and +9.8% +/- 14.0%, respectively; p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Fourteen patients (6 boys; ages 4.8 to 10.8 years) were studied.
Summary · context
The patients were divided into two groups comparable in sex, age, height, and clinical severity of OI; seven patients (three boys) were treated for 12 months with hGH at a dosage of 0.2 mg/kg per week (0.6 IU/kg per week), in six injections subcutaneously, and seven were followed as control subjects.
Report a problemFND-0880433408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.